Cargando…
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
Diabetes is a global health emergency projected to affect 642 million people by 2040. Type 2 diabetes (T2D) represents 90% of diabetes cases and is associated with a range of cardiovascular (CV) risk factors that are more than double the incidence of CV disease and significantly increase mortality r...
Autores principales: | Schernthaner, Guntram, Jarvis, Sarah, Lotan, Chaim, Prázný, Martin, Wanner, Christoph, Wascher, Thomas C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245806/ https://www.ncbi.nlm.nih.gov/pubmed/28144148 http://dx.doi.org/10.2147/TCRM.S121804 |
Ejemplares similares
-
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
por: Schernthaner, Guntram, et al.
Publicado: (2017) -
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
por: Czupryniak, Leszek, et al.
Publicado: (2021) -
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
por: Schernthaner, Guntram, et al.
Publicado: (2018) -
Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
por: Hu, Ying
Publicado: (2019) -
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)